Patients Pregnant Women With or Without Primary Antiphospholipid Antibody Syndrome

Launched by IRCCS SAN RAFFAELE · Mar 15, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how certain markers in the placenta can help predict the risk of a serious condition called preeclampsia (PE) in pregnant women who have a condition known as primary antiphospholipid syndrome (APS). Preeclampsia can lead to health problems for both the mother and baby, so understanding these markers could be very helpful. The researchers will measure levels of specific substances in the blood of women during different stages of their pregnancies to see how they relate to the risk of developing PE.

To participate, women must be aged 18 to 45 and either have a diagnosis of primary APS (Group 1) or have had at least one full-term pregnancy without APS (Group 2). Participants will be monitored throughout their pregnancy, and the study aims to gather important information that could help improve care for pregnant women at risk of complications. If you or someone you know fits the criteria and is interested, this trial could provide valuable insights into managing pregnancy health.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Group 1
• • 1. Pregnant patients between the ages of 18 and 45 years.
• • 2. Diagnosis of primary APS, according to international classification criteria.
• • Group 2
• • 1. Pregnant patients between the ages of 18 and 45 years.
• • 2. Patients with at least one previous full-term pregnancy.
• • 3. No diagnosis of APS, according to international classification criteria.
• Exclusion Criteria:
• • Group 1
• • 1. PMA pregnancies.
• • 2. Known chronic pathology in gestational period such as chronic essential hypertension, neurological pathology
• • 3. Previous thrombotic event
• • 4. Chronic renal failure not related to AD
• • 5. Previous history of oncology
• • Group 2
• • 1. Pregnancy by PMA.
• • 2. Previous history of polyabortion and/or late pregnancy complications.
• • 3. Known chronic pathology in gestational period such as chronic essential hypertension, neurological pathology
• • 4. Previous thrombotic event
• • 5. Previous history of oncology